#1
|
|||
|
|||
Àëåðãè÷åñêèé ðèíîñèíóñèò ó ðåáåíêà 1ã9ìåñ
Ïîìîãèòå ïîæàëóéñòà! Ìîåìó ñûíó 1ã9ìåñ. Áåñïîêîèò íàñìîðê óæå ìåñÿöåâ 5, äíåì ïî÷òè âñåãäà õîäèò ñ îòêðûòûì ðòîì. Ñèëüíî íå îáðàùàëà âíèìàíèå, ò.ê. íî÷üþ âñåãäà ñïàë ñ çàêðûòûì ðòîì, ÿ âîîáùå äóìàëà, ÷òî ìîæåò ýòî ó íåãî ïðèâû÷êà òàêàÿ îñòàëàñü (íàñìîðê ñèëüíûé ïîÿâèëñÿ â 1ã4ì êîãäà ïîëåçëè îäíîâðåìåííî 8 çóáîâ). Îáîñòðèëñÿ íàñìîðê ìåñÿö íàçàä â íà÷àëå ìàÿ, êîãäà êàê ðàç íà óëèöå ïîòåïëåëî è âèäèìî ÷òî-òî çàöâåëî. Ðåçêî óõóäøèëîñü ñîñòîÿíèå - åñëè ðàíüøå ïðîñòî íåìíîãî òåêëî èç íîñà (ñïàñàëèñü ïðîìûâàíèåì íîñà àêâà-ìàðèñîì), òî â ìà÷àëå ìàÿ ñòàëî çàêëàäûâàòü íîñ âî âðåìÿ ñíà, ðåáåíîê ïåðåñòàë íîðìàëüíî ñïàòü, íå ìîæåò äûøàòü íîñîì, õâàòàåò âîçäóõ ðòîì, îïÿòü ïûòàåòñÿ äûøàòü íîñîì, çàäûõàåòñÿ, îòêðûâàåò ðîò è ò.ä.  êîíöå êîíöîâ ïðîñûïàåòñÿ. ×åðåç íåñêîëüêî äíåé îòåêëî âåêî ïîä îäíèì ãëàçîì, çàòåì ïîä äðóãèì. Ïðè ýòîì êðàñíîòû ãëàç íå áûëî, õîòÿ ðåáåíîê ïîñòîÿííî òåð ãëàçà. Òîãäà ñïàñëè òîëüêî íàçíà÷åííûå îêóëèñòîì êàïëè äåêñà-ãåíòàìèöèí. Íàçíà÷åííîå ËÎÐîì ëå÷åíèå (íàçèâèí, èçîôðà) îò çàëîæåííîñòè íîñà íå ïîìîãëî ñîâñåì, ñèòóàöèÿ íå èçìåíèëàñü. È 12 ìàÿ ìû ñ ðåáåíêîì ïîïàëè â áîëüíèöó ñ äèàãíîçîì ïíåâìîíèÿ. Íà ñëåä.äåíü óøëè, äîëå÷èâàëèñü äîìà (öåôîòàêñèì, èíãàëÿöèè ñ áåðîäóàëîì è 3 èíãàëÿöèè ñ ïóëüìèêîðòîì). Ðåáåíîê ïðè ýòîì âûãëÿäåë áîëüíûì òîëüêî îäèí äåíü, 15 ìàÿ õðèïû â ëåãêèõ åùå ïðîñëóøèâàëèñü, íî 19 âñå áûëî ÷èñòî. Ïîòîì âðà÷ íàì ñêçàëà, ÷òî âèäèìî ïíåâìîíèÿ ÿâèëàñü ñëåäñòâèåì àëåðãè÷åñêîãî áðîíõîñïàçìà, âîâðåìÿ íå ñíÿòîãî òåì æå áåðîäóàëîì (à ìû è ïîíÿòèÿ íå èìåëè, ÷òî ó íàñ ðåáåíîê òàêîé àëåðãèê, íó òåêëî èç íîñà, íó íîæêè êðàñíûå, íî ó êîãî ýòîãî íåò). ×òî èíòåðåñíî, ïîêà ðåáåíîê áîëåë ïíåâìîíèåé - êîæà î÷èñòèëàñü, îòåê ïîä ãëàçàìè ïðîøåë, íîñèê ñòàë ñóõèì è íîðìàëüíî äûøàë. Òîëüêî ðåáåíîê íåìíîãî îïðàâèëñÿ îò ïíåâìîíèè, êàê ñðàçó îïÿòü çàëîæèëî íîñ.
Íà ñåé÷àñ: íîñ çàëîæåí, îòäåëÿåìîãî ìàëî (òîëüêî ïîñëå ñíà íåìíîãî æåëòûõ ñîïëåé), íîðìàëüíî ñïèò íî÷üþ òîëüêî ïîñëå çàêàïûâàíèÿ ñîñóäîñóæèâàþùèõ êàïåëü, è òî äî óòðà íå õâàòàåò, ãëàçà òðåò, íî âðîäå ïðèïóõëîñòè íåò, íåïðèÿòíûé çàïàõ èëè èçî ðòà èëè èç íîñà ïîñëå ñíà. Ñîñóäîñóæèâàþùèå êàïàþ óæå 6 äíåé, ïîíèìàþ, ÷òî íàäî ïðåêðàùàòü, íî ÷òî äåëàòü, êàê ïîìî÷ü ðåáåíêó? Ñåãîäíÿ ñõîäèëà ñ íèì íà êîíñóëüòàöèþ ê ËÎÐ â ïëàòíóþ êëèíèêó, îí ïîñìîòðåë ñëèçèñòóþ, ñêàçàë, ÷òî îíà ñèíþøíàÿ è ïîýòîìó ñäåëàë âûâîä, ÷òî âñå-òàêè ýòî àëåðãè÷åñêîé ïðèðîäû. Ïîñòàâèë äèàãíîç "àëåðãè÷åñêèé ðèíîñèíóñèò". Íàçíà÷èë ëå÷åíèå: çèðòåê (ïèòü ïî 5 êàïåëü 1 ð/ä âîçìîæíî äëèòåëüíî). 5% òèîñóëüôàò íàòðèÿ ïî 4 êàïëè â íîñ 3 ð/ä 7 äíåé, ïîòîì ïåðåðûâ 7 äíåé è ïîâòîðèòü. Ïîñëå îêîí÷àíèÿ ëå÷åíèÿ òèîñóëüôàòîì íàòðèÿ - 5% àìèíîêàïðîíîâàÿ êèñëîòà ïî 6 êàï 2 ð/ä + 2% ïðîòàðãîë 10 äíåé. ß íå çíàþ, ÷òî òàêîå òèîñóëüôàò íàòðèÿ è àìèíîêàïðîíîâàÿ êèñëîòà è êàêîå îíè èìåþò îòíîøåíèå ê àëëåðãè÷åñêîìó ðèíîñèíóñèòó, íî ìåíÿ ñìóòèëî íàçíà÷åíèå ïðîòàðãîëà, ò.ê. ÿ ÷èòàëà çäåñü íà ñàéòå, ÷òî åãî íå íàäî èñïîëüçîâàòü. Ýòî âûçâàëî íåäîâåðèå ê äîêòîðó. ß êîíå÷íî æå ñâîæó ðåáåíêà ê äðóãîìó âðà÷ó, íî ìíå íóæíî ÷òî-òî äåëàòü óæå ñåé÷àñ, âåäü îí íå ñïèò áåç ñîñóäîñóæèâàþùèõ, à ÿ êàïàþ èõ (òèçèí êñèëî äåòñêèé) óæå 6 äíåé. Âðà÷ ýòîò ñêàçàë, ÷òî êîíå÷íî æå ëå÷åíèå â òàêèõ ñèòóàöèÿõ îáû÷íî çèðòåê + íàçîíåêñ, íî íàçîíåêñ íå ïðèìåíÿåòñÿ ó äåòåé äî 2-õ ëåò. Âîò è íå ïîíÿòíî, ÷åì ëå÷èòü îòåê. Çèðòåê ÿ ñåãîäíÿ ðåáåíêó äàëà, íàäåþñü, ÷òî áóäåò ýôôåêò, íî áóäåò ëè îí è äîñòàòî÷íî ëè òàêîãî ëå÷åíèÿ? È êàïàòü ëè åìó òèîñóëüôàò íàòðèÿ è ÀÊÊ? Êàêîå ëå÷åíèå âû áû ïîðåêîìåíäîâàëè â íàøåì ñëó÷àå, êàê ïîìî÷ü ðåáåíêó è íå çàïóñòèòü ñèòóàöèþ åùå äàëüøå? |
#2
|
||||
|
||||
Äåéñòâèòåëüíî, çîëîòûì ñòàíäàðòîì ëå÷åíèÿ àëëåðãè÷åñêîãî ðèíèòà ó äåòåé ïðè ïîäòâåðæäåííîì äèàãíîçå ÿâëÿåòñÿ íàçîíåêñ(áåç àíòèãèñòàìèííûõ). Òèîñóëüôàò íàòðèÿ ïðè àëëåðãè÷åñêîì ðèíèòå íå ïðèìåíÿåòñÿ íèêîãäà(è ó âçðîñëûõ òîæå). Ïðîòàðãîë è àìèíîêàïðîíîâàÿ êèñëîòà - àíàëîãè÷íî.
Íåîáõîäèìî óâëàæíÿòü ñëèçèñòóþ, îòêàçàòüñÿ îò ñîñóäîñóæèâàþùèõ è ðåøàòü âîïðîñ î ïðèìåíåíèè ìåñòíûõ ñòåðîèäîâ - è âñå ýòî ñ âðà÷îì î÷íî. |
#3
|
|||
|
|||
Ñïàñèáî çà îòâåò!
Íî êàê æå ïðèìåíÿòü ìåñòíûå ñòåðîèäû, åñëè Íàçîíåêñ òîëüêî ñ äâóõ ëåò? Èëè åñòü êàêèå-òî äðóãèå ñðåäñòâà? ß â áëèæàéøèå äíè äóìàþ ïîïàäó íà î÷íûé ïðèåì ê äðóãîìó âðà÷ó (íàäåþñü, ÷òî îí íå áóäåò âûïèñûâàòü Ïðîòàðãîë è èæå ñ íèì), íî ïðîñòî õîòåëîñü áû çíàòü, ÷åãî æäàòü. Åùå âîïðîñ - ìàñëà äëÿ óâëàæíåíèÿ íå èñïîëüçóþòñÿ (íàïðèìåð, êàêèå-íèáóäü êàïëè íà ìàñëÿíîé îñíîâå òèïà Ïèíîñîëà). Ìîè ðîäñòâåííèêè ìåíÿ çàìó÷èëè, âñå óáåæäàþò çàêàïàòü ðåáåíêó Âèòàîí (áàëüçàì Êàðàâàåâà), à îí âðîäå äàæå ðåãèñòðàöèîííîãî óäîñòîâåðåíèÿ êàê ëåêóàðñòâî íå èìååò, óáåæäàþò, ÷òî àáñîëþòíî áåçîïàñåí äàæå äëÿ ìàëåíüêèõ äåòåé. ß â ýòî íå âåðþ, äà è â åãî ýôôåêòèâíîñòü òîæå, íî õîòåëîñü áû óñëûøàòü ìíåíèå âðà÷à. Êàê âû îòíîñèòåñü ê ýòèì êàïëÿì? |
#4
|
||||
|
||||
Áàëüçàì Êàðàâàåâà - ñðåäñòâî ñ íåäîêàçàííîé ýôôåêòèâíîñòüþ, ñ íåèçâåñòíûì ýôôåêòîì â ïðèíöèïå. Êîíå÷íî, íå íóæíî êàïàòü åãî ðåáåíêó.
Íàñ÷åò ñòåðîèäîâ - íàäî ðåøàòü âîïðîñ ñ âðà÷îì î÷íî, äà è äî 2 ëåò âàì óæå ìåíüøå 3 ìåñÿöåâ, íàñêîëüêî ÿ ïîíèìàþ. |
#5
|
|||
|
|||
Ñïàñèáî áîëüøîå çà îòâåò!
Èçâèíèòå çà ãëóïûé âîïðîñ. Ïî÷åìó íå íàäî äàâàòü àíòèãèñòàìèííûå, åñëè íàñìîðê àëëåðãè÷åñêèé? ß â ïðèíöèïå è ñàìà âèæó, ÷òî ýôôåêòà îò íèõ íåò, è ìîé ìóæ, ó êîòîðîãî òîæå êàê ó ðåáåíêà àëëåðãè÷åñêèé ðèíèò è ïîëèïîç, ãîâîðèò, ÷òî åìó îíè íå ïîìîãàþò. Íî òîãäà îíè âîîáùå êîãäà-íèáóäü íóæíû ðåáåíêó-àëëåðãèêó? Ìîæåò èìååò ñìûñë èõ äàâàòü ÏÅÐÅÄ íà÷àëîì öâåòåíèÿ? Èëè àíòèãèñòàìèííûå ñîâñåì áåñïîëåçíû? È åùå òàêîé ìîìåíò.  âûõîäíûå áûëè íà äà÷å, ïîñëå äà÷è ó ðåáåíêà èç íîñà ïîòåêëè ïðîçðà÷íûå ñîïëè, ìíîãî. Èç íîçäðè, êîòîðàÿ çàëîæåíà, ïîñòîÿííî âûòåêàþò (èç äðóãîé äóìàþ ïî çàäíåé ñòåíêå ñòåêàþò). Æåëòûå ãóñòûå, êàêèå áûëè ïî óòðàì, èç÷åçëè. ß ïîíèìàþ, ÷òî íå âèäÿ ðåáåíêà ñëîæíî äåëàòü âûâîäû, íî ìîæåò ìîæíî ñêàçàòü, íå îçíà÷àåò ëè ýòî, ÷òî ñèòóàöèÿ óëó÷øàåòñÿ, èëè íàîáîðîò? Ê âðà÷ó çàïèñàëèñü òîëüêî ÷åðåç 2 äíÿ. |
#6
|
||||
|
||||
Êàê ðàç æåëòûå ãóñòûå èëè çåëåíûå ñîïëè ñâèäåòåëüñòâóþò îá óëó÷øåíèè. À ïðîçðà÷íûå ñîïëè - ýòî õàðàêòåðíûé ïðèçíàê àëëåðãè÷åñêîãî ðèíèòà.
Îòíîñèòåëüíî àíòèãèñòàìèííûõ - êàñàåìî èìåííî àëëåðãè÷åñêîãî ðèíèòà äîñòàòî÷íî íàçîíåêñà, òîãäà àíòèãèñòàìèííûå íå íóæíû. |
#7
|
|||
|
|||
Öèòàòà:
Åñòü ìíåíèå, ÷òî ëå÷åíèå àëëåðãè÷åñêîãî ðèíèòà ó äåòåé äî òðåõ ëåò íà÷èíàþò ñ àíòèãèñòàìèííûõ ïðåïàðàòîâ âòîðîãî ïîêîëåíèÿ (çèðòåê) è óæå òîëüêî ïðè íåýôôåêòèâíîñòè àíòèãèñòàìèííûõ íàçíà÷àþò íàçîíåêñ. |
#8
|
|||
|
|||
Ñåãîäíÿ áûëè ó âðà÷à, îíà ïîäòâåðäèëà àëëåðãè÷åñêèé õàðàêòåð íàñìîðêà ó ðåáåíêà. Íàçíà÷èëà Íàçîíåêñ ïî 1 äîçå 1 ðàç â äåíü óòðîì â êàæäóþ íîçäðþ ïîñëå îáÿçàòåëüíîãî òóàëåòà íîñà, êîòîðûé âêëþ÷àåò â ñåáÿ: ïðîìûâàíèå àêâàìàðèñîì/àêâàëîðîì, ïîòîì î÷èñòêà àñïèðàòîðîì, åñëè ïîñëå âñåãî ýòîãî íîñ çàëîæåí, òî âèáðîöèë êàïëè. È òîëüêî êîãäà íîñ áóäåò äûøàòü íîðìàëüíî - Íàçîíåêñ. Ñêàçàëà, ÷òî î÷åíü âàæíî ïøèêàòü Íàçîíåêñ èìåííî êîãäà íîñ õîðîøî ïðîõîäèì. ß ïîíèìàþ íà ñ÷åò òîãî, ÷òîáû íå áûëî â íîñó âûäåëåíèé, íî ñíèìàòü îòåê ñîñóäîñóæèâàþùèìè ìíå êàê-òî íå î÷åíü áû õîòåëîñü. À åñëè îòåê áóäåò äëèòåëüíî ñîõðàíÿòüñÿ, âñå ðàâíî íàäî ñîñóäîñóæèâàþùèå? Ïðîñòî ÿ òîëüêî â âîñêðåñåíüå çàêîí÷èëà êàïàòü åìó äåòñêèé Òèçèí (êàïàëà 9 äíåé), õîòåëîñü áû îêîí÷àòåëüíî óéòè îò ñîñóäîñóæèâàþùèõ, õîòü â âèáðîöèëå è äðóãîå äåéñòâóþùåå âåùåñòâî. Ïîäñêàæèòå, êàê âû äóìàåòå, íàñêîëüêî îáÿçàòåëüíî èìåííî ñíèìàòü îòåê äî Íàçîíåêñà? Íå õîòåëîñü áû äàâàòü ðåáåíêó ëåêàðñòâî, åñëè îò íåïðàâèëüíîãî ïðèìåíåíèÿ îò íåãî íå áóäåò ýôôåêòà, íî òàêæå íå õîòåëîñü áû è ëèøíèõ ëåêàðñòâ.
|
#9
|
||||
|
||||
Öèòàòà:
Íàïðèìåð, çäåñü A review of the clinical studies assessing the efficacy of intranasal corticosteroids (INS) for rhinorrhea is presented. Many clinical studies and several meta-analyses conclusively demonstrate that, in addition to being safe and well-tolerated, INS are more effective than other agents (including oral and intranasal antihistamines) across the spectrum of AR symptoms, including rhinorrhea and nasal congestion.  ñîîòâåòñòâóþùåì ãàéäëàíñå A Intranasal glucocorticosteroid with bioavailability of < 1%, such as fluticasone propionate or mometasone furoate, should be considered as a treatment option for allergic rhinitis and allergic conjunctivitis (pg 56). Grade A, Level 1++ Äàëåå, ñìîòðèì åùå ðåêîìåíäàöèè The treatment of allergic rhinitis is mainly based on allergen avoidance, pharmacological treatment and specific immunotherapy. For mild symptoms of seasonal or perennial allergic rhinitis topical or nonsedating second generation oral H1-antihistamines or chromones are advised. If the patient presents symptoms of long duration or nasal obstruction is dominant, intranasal steroids should be used, which have proved to be an effective and safe form of therapy for allergic rhinitis. A combination of oral antihistamines and steroids are possible and recommended if one of these agents alone does not provide sufficient relief. If necessary this regimen is supplemented with topical antihistamines or chromone eyedrops. In cases of severe nasal obstruction, a short course of oral steroids or topical decongestants, which both should not be given longer than ten days, is recommended. Intramuscular corticosteroids should not be given, due to the suppression of adrenal glands. In addition it is important to prevent exposure to the allergen. If the treatment is not effective, further investigations should be done to exclude other nasal diseases (polyposis nasi, anatomical anomalies, chronic sinusitis). Òî åñòü ïðè âûðàæåííîì çàòðóäíåíèè íîñîâîãî äûõàíèÿ ðåêîìåíäîâàíî ïðèìåíÿòü íàçàëüíûå ñòåðîèäû, à ñî÷åòàíèå àíòèãèñòàìèííûõ è ñòåðîèäîâ âîçìîæíî òîëüêî ïðè íåýôôåêòèâíîñòè èõ ïî îòäåëüíîñòè. Äà, èçíà÷àëüíî ïðåäïîëàãàåòñÿ, ÷òî àíòèãèñòàìèííûå ìîãóò áûòü ïðåïàðàòàìè ïåðâîé ëèíèè. Íî, ïðè ýòîì, îíè îáëàäàþò áîëåå íèçêîé ýôôåêòèâíîñòüþ, íåæåëè íàçàëüíûå ñòåðîèäû. Ñîâåðåìåííûå íàçàëüíûå ñòåðîèäû - ìîìåòàçîí - íå îáëàäàþò ñèñòåìíûì äåéñòâèåì. Ïîýòîìó èìåííî èõ ðåêîìåíäóþò êàê ïðåïàðàòû âûáîðà ïðè ëå÷åíèè àëëåðãè÷åñêîãî ðèíèòà ó âçðîñëûõ è äåòåé(ýòî ÿ è íàçûâàþ "çîëîòûì ñòàíäàðòîì" - ïðåïàðàòàìè âûáîðà) Intranasal corticosteroids—Intranasal corticosteroids may be the most effective medications for the overall control of allergic rhinitis symptoms. They relieve sneezing, itching, and rhinorrhea, and also nasal congestion. Maximal effect may take from 1 to 2 weeks after the onset of their use. Their effectiveness depends on regular use and an adequate nasal airway for application. They act on the late-phase reaction and therefore prevent a significant influx of inflammatory cells. The newer formulations (mentioned below) have minimal systemic absorption with no systemic side effects, and they have been approved for use in children. They have no systemic side effects with regard to HPA axis suppression and do not affect long-bone growth in children. In young adults and children, they are considered the drugs of choice in the treatment of allergic rhinitis. Local side effects, such as dryness and epistaxis, can be reduced by careful patient instruction on their use and also the regular, concomitant use of intranasal saline. Commonly available intranasal corticosteroids in the United States include triamcinolone (eg, Nasacort), budesonide (eg, Rhinocort), fluticasone (eg, Flonase), and mometasone (eg, Nasonex). |
#10
|
||||
|
||||
Íàçîíåêñ íå íóæäàåòñÿ â ïðèìåíåíèè ñîñóäîñóæèâàþùèõ ïåðåä åãî èñïîëüçîâàíèåì, ðàçóìååòñÿ.
|
#11
|
|||
|
|||
Ñïàñèáî çà ïðèâåäåííûå öèòàòû!
Öèòàòà:
Öèòàòà:
ÈÌÕÎ, âíà÷àëå íóæíî èñïîëüçîâàòü áåçîïàñíûå ñðåäñòâà (àíòèãèñòàìèííûå âòîðîãî ïîêîëåíèÿ, êðîìîíû), à ïðè íåýôôåêòèâíîñòè çàìåíèòü èõ íà íàçîíåêñ. ÈÌÕÎ, ñàì ïî ñåáå îãðàíè÷åííûé îïûò èñïîëüçîâàíèÿ íàçîíåêñà ó äåòåé ðàííåãî âîçðàñòà óæå íàìåêàåò íà òî, ÷òî â ýòîì âîçðàñòå áåç íàçîíåêñà óäàåòñÿ îáîéòèñü è ýòî íå ïðåïàðàò âûáîðà. |
#12
|
|||
|
|||
Öèòàòà:
Äîñòàòî÷íî ÷àñòî ïðèõîäèòñÿ ïðèìåíÿòü ñîñóäîñóæèâàþùèå ñðåäñòâà ïåðåä èñïîëüçîâàíèåì íàçîíåêñà. Óâåðåí, ÷òî ýòî äîïóñòèìàÿ òàêòèêà â ïåðâûå íåñêîëüêî äíåé. |
#13
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Âòîðûì èñòî÷íèêîì áûëî ðóêîâîäñòâî ïî îòîðèíîëàðèíãîëîãèè Current Diagnosis & Treatment in Otolaryngology - Head & Neck Surgery/ ß èñêàëà, ïðîñòî íàáðàâ â ïàáìåäå ëå÷åíèå àëëåðãè÷åñêîãî ðèíèòà ó äåòåé. Öèòàòà:
Íàøëà èññëåäîâàíèå, êîòîðîå äîêàçûâàåò ïðåèìóùåñòâî èñïîëüçîâàíèÿ òîëüêî ìîìåòàçîíà ïåðåä èñïîëüçîâàíèåì êîìáèíàöèè ïðåïàðàòîâ èëè àíòèãèñòàìèííûõ âòîðîãî ïîêîëåíèÿ. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] BACKGROUND: Intranasal corticosteroids and nonsedating antihistamines are the drug classes most often prescribed to treat allergic rhinitis (AR). Treatment guidelines recommend a combination of these agents for moderate-to-severe AR. However, clinical studies have found that combining an antihistamine with an intranasal corticosteroid provides few or no advantages over monotherapy with an intranasal corticosteroid. OBJECTIVE: To compare the efficacy of mometasone furoate nasal spray (NS) plus loratadine with that of monotherapy with the individual agents in patients 12 years and older with at least a 2-year history of seasonal AR. METHODS: In a multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study, 702 patients were randomized to receive mometasone furoate NS, 200 microg, plus loratadine, 10 mg (n = 169); mometasone furoate NS, 200 microg (n = 176); loratadine, 10 mg (n = 181); or placebo (n = 176) once daily for 15 days. Primary efficacy variables were total nasal symptom score (TNSS) and total symptom score (TSS) as recorded on diary cards. RESULTS: No statistically significant differences were observed between mometasone furoate NS plus loratadine and mometasone furoate NS monotherapy for the primary efficacy variables. For TNSS and TSS, all 3 active drug therapies were more effective than placebo (P < or = .02). Both mometasone furoate NS treatment regimens were more effective than loratadine or placebo for TNSS (P < .01 for both) and TSS (P < or = .03 for both), whereas loratadine was more effective than placebo for TNSS only (P = .02). CONCLUSIONS: Combination therapy with mometasone furoate NS and loratadine provided benefits similar to monotherapy with mometasone furoate NS for the symptoms of seasonal AR. Therefore, mometasone furoate NS monotherapy was shown to be an effective treatment for seasonal AR. |
#14
|
||||
|
||||
Åùå îäèí ìîìåíò - àëëåðãè÷åñêèé ðèíèò ó äåòåé ìëàäøå 2 ëåò âñòðå÷àåòñÿ ðåæå. Âîçìîæíîñòü èññëåäîâàíèÿ íèæå ó ýòîé âîçðàñòíîé ãðóïïû. Åñòü ðàçíèöà ìåæäó òåì, ÷òî ïðåïàðàò íå ïðèìåíÿåòñÿ, ïîòîìó ÷òî íåáåçîïàñåí, èëè ïðåïàðàò íå ïðèìåíÿåòñÿ, ïîòîìó ÷òî çàòðóäíåíî äîêàçàòåëüñòâî áåçîïàñíîñòè.
Òî, ÷òî ÿ íàøëà ïîêà: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Mometasone furoate (Nasonex) is a high-potency intranasal corticosteroid available for the treatment and/or prophylaxis of the nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). In the EU, it is approved for use in patients aged > or =6 years and, in the US, it is approved as a treatment in patients aged > or =2 years and as prophylaxis in those > or =12 years of age.Extensive experience in both clinical trials and the clinical practice setting has firmly established the efficacy and good tolerability profile of intranasal mometasone furoate in children and adults with PAR or SAR. Thus, intranasal mometasone furoate is a useful first-line option for the treatment and prophylactic management of these conditions, including in children as young as 2 years of age in some countries and 6 years of age in others. |